Use of catecholamines in cardiac donors: What is the real limit? [1]

Journal of Heart and Lung Transplantation

Volumn 23, Issue 7, 2004, Pages 916-917

  Chamorro, C ^a   Silva, J A ^a   Segovia, J ^a   Romera, M A ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR; CATECHOLAMINE DERIVATIVE; DOBUTAMINE; DOPAMINE; NORADRENALIN; VASOCONSTRICTOR AGENT;

ARTERIAL PRESSURE; BRAIN DEATH; CORONARY ARTERY BLOOD FLOW; DIABETES INSIPIDUS; FOLLOW UP; HEART FAILURE; HEART GRAFT; HEART MUSCLE; HEART TRANSPLANTATION; HUMAN; LETTER; ORGAN DONOR; PRIORITY JOURNAL; VASODILATATION;

DOBUTAMINE; DOPAMINE; HEART TRANSPLANTATION; HUMANS; NOREPINEPHRINE; TISSUE AND ORGAN HARVESTING; TISSUE DONORS;

EID: 3242711987     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2003.07.026     Document Type: Letter

References (5)

1. Zaroff J.G., Rosengard B.R., Armstrong W.F., et al. Maximizing use of organs recovered from the cadaver donor cardiac recommendations. J Heart Lung Transplant. 21:2002;1153-1160
2. Silva J.A., Chamorro C., Romera M.A., et al. Employment of high doses of catecholamines in heart donors is not associated with development of early graft failure in the recipient. Intens Care Med. 28:(suppl):2002;S66
3. Bruinsma G.J., Nederhoff M.G.J., van de Kolk C.W.A., et al. Bio-energetic response of the heart to dopamine following brain death-related reduced myocardial workload a phosphorus-31 magnetic resonance spectroscopy study in the cat. J Heart Lung Transplant. 18:1999;1189-1197
4. El Oakley R.M., Yonan N.A., Simpson B.M., et al. Extended criteria for cardiac allograft donors a consensus study. J Heart Lung Transplant. 15:1996;255-259
5. Szabo G., Hackert T., Sebening C., et al. Modulation of coronary perfusion pressure can reverse cardiac dysfunction after brain death. Ann Thorac Surg. 67:1999;18-26